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Abstract
Background
Methyl-aminolevulinate photodynamic therapy (MAL-PDT) is an excellent option for the
treatment of basal cell carcinoma (BCC). However, up to 25% of cases are resistant to this
treatment modality.
Objective
The aim of this study was to identify potential biomarkers of BCC response to MAL-PDT.
Material and methods
Clinical, histological, and immunohistochemical (p53, Ki-67, CD-31, COX2, β-catenin,
EGFR, and survivin) variables were analyzed in a retrospective study of consecutive BCC
patients treated with MAL-PDT at the San Jorge Hospital, Huesca, Spain between January
2006 and December 2015. To deepen on these markers, the effects on p53 and cyclin D1
expression, in vitro response to MAL-PDT of 2 murine BCC cell lines (ASZ and BSZ), was
also evaluated.
Results
The retrospective study examined the response to MAL-PDT of 390 BCCs from 182
patients. The overall clinical response rate was 82.8%, with a mean follow-up time of 35.96
months (SD = 23.46). Immunohistochemistry revealed positive p53 in 84.6% of responders
but only 15.4% of nonresponsive tumors (p = 0.011). Tumors with increased peripheral pali-
sading of basal cell islands to immunostaining β-catenin responded poorly to PDT (p =
0.01). In line with our findings in patients, in vitro studies revealed a better response to PDT
in the p53-positive ASZ cell line than the p53-negative BSZ cell line (p<0.01).
Multivariate analysis revealed that the following variables were significantly associated
with response to PDT: age, nBCC, presence of peritumoral inflammatory infiltrate, and p53
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immunopositivity. Patients with positive p53 immunostaining were 68.54 times more likely to
achieve cure than p53-negative patients (CI95% 2.94–159.8)
Conclusion
Our finding suggest that certain clinicopathological and immunohistochemical variables,
particularly p53 expression, may serve as indicators of BCC response to MAL-PDT, and
thus facilitate the selection of patients who are most likely to benefit from this therapy.
Introduction
Methyl-aminolevulinate (MAL) photodynamic therapy (PDT) is an excellent option for the
treatment of superficial (sBCC) and nodular (nBCC) basal cell carcinoma (strength of recom-
mendation, A; quality of evidence, 1).[1] The clearance rate after 2 cycles of MAL-PDT is 91%
after 3 months of follow-up, decreasing to 76% after 5 years of follow-up.[1] However, despite
good response rates, primary or acquired resistance means that some tumors do not respond
to treatment.[2]
Treatment resistance contributes to tumor progression and is associated with a worse prog-
nosis. While resistance to chemotherapy and radiotherapy has been well-studied,[3] PDT
resistance has received less research attention.[4,5] Common mechanisms involving extrinsic
and intracellular factors may underlie resistance to PDT and other antitumoral therapies.
Extrinsic factors include those pertaining to the tumor vasculature and stroma.[5] Intracellular
alterations also may contribute to poor treatment responses to PDT.[4] Intracellular mecha-
nisms implicated in PDT resistance include differences in the incorporation and expulsion
rates of drugs; alterations in intracellular transport; loss of drug activity; increases in drug inac-
tivation; and, in particular, the mutation and/or activation of certain genes implicated in BCC
formation or altered following treatment.[6]
In this study, we sought to characterize clinical, histological, and molecular factors impli-
cated in BCC response to MAL-PDT. To this end, we analyzed skin samples from BCC
patients treated with MAL-PDT and studied the effects of MAL-PDT in 2 representative
murine BCC cell lines, ASZ001 (ASZ) and BSZ2 (BSZ).[7]
Patients and methods
Design
In this retrospective observational study we analyzed samples from all consecutive patients
who were clinically assisted by dermoscopy, and/or biopsy histologically diagnosed with BCC
and treated with MAL-PDT between January 2006 and December 2015 at the Dermatology
Service of San Jorge Hospital (Huesca, Spain). Histological samples were archived by the hos-
pital’s Pathology Service. The following inclusion criteria were applied: clinical and dermo-
scopic diagnosis of BCC, a clinical follow-up period of>3 months, and available clinical and
pathological records.
MAL-PDT treatment
After lesion curettage or debulking, patients had received PDT with MAL cream (160 mg/g of
Metvix; Galderma, France) following the standard procedure.[8] In all cases, the cream had
been applied and incubated for 3 hours with occlusion, and subsequently exposed to 37 J/cm2
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of illumination with a coherent, monochromatic red light source with a diode system (630 nm,
Aktilite lamp; PhotoCure ASA, Oslo, Norway). The protocol was 2 sessions one week apart,
each case was evaluated individually.
Clinical variables
The clinical records of all patients were reviewed and data gathered for the following variables:
BCC subtype (nBCC or sBCC), age at onset, sex, phototype (Fitzpatrick scale I–VI), and tumor
size and location.
Response-related variables
Clinical response was evaluated at the end of patient follow-up assisted with dermatoscopy
and biopsy was performed in 63 cases. All patients were followed-up every 3 months for the
first year after treatment and subsequently every 6 months up to a maximum of 6 years.
Histological variables
Hematoxylin-eosin-stained sections were examined using an Olympus BX61 microscope
(Olympus, PA, USA) coupled to a DP50 CCD digital camera (Olympus Optical Co. Ltd,
Tokyo, Japan).
The following variables were evaluated: tumor thickness; histological subtype (superficial or
nodular); peritumoral stroma (loose, dense or mucinous); presence/absence of elastosis; pres-
ence/absence of necrosis and/or ulceration; loss/enhancement peripheral palisading; and pres-
ence of peritumoral inflammatory infiltrate greater than 50% of the tumor area and
vascularization.
Immunohistochemical variables
The expression of biological markers implicated in PDT resistance, based on previous findings
by our group,[4] was also evaluated using monoclonal antibodies against a range of proteins
(S1 Table).
Sections were immunostained (TechMate 500, BioTech Solutions, Dako, Denmark) and
then incubated with a detection kit (Chemate, code K4001, Dako) according to manufacturer’s
recommendations. Immunostaining was visualized using 3-amino-9-ethylcarbazole chromo-
gen solution (Dako). Heat-induced epitope retrieval was achieved using a pressure cooker.
Representative sections and positive and negative controls were examined.[4]
For immunohistochemical evaluation of p53 and Ki-67 expression the tumor area with the
highest levels of immunoexpression “hot spots” was identified and the percentage of cells with
nuclear positivity in a high-power field (400×) was estimated. Expression of EGFR, survivin, β-
catenin, and COX-2 was semiquantitatively assessed by classifying expression intensity as fol-
lows: 0, absence of staining; 1, mild staining (0–33% tumoral cell staining); 2, moderate stain-
ing (34–66% tumoral cell staining); and 3, intense staining (67–100% tumoral cell staining).
For evaluation of CD-31 expression, vessels within the tumor with the highest levels of CD-31
expression were selected (“hot spot”) was identified and the number of CD-31-positive vessels
in a high-power field (400×) was quantified. β-catenin immunostaining was categorized by
expression intensity as well as reinforcement of peripheral palisading or not, while survivin
expression was defined as focal or diffuse and expression intensity. All samples were simulta-
neously evaluated by 2 pathologists who were blind to sample identity.
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In vitro studies
Cell cultures. In vitro studies were performed using cell lines obtained from BCCs
induced in a ptch1+/- mouse exposed to UV irradiation (ASZ001, ASZ) and in a ptch1+/-,
K14CreER2/+; p53fl/fl mouse exposed to γ radiation (BSZ2, BSZ).[7] Cells were grown in
DMEM (Dulbecco’s modified Eagle’s medium) supplemented with 10% (v/v) fetal bovine
serum and 1% antibiotic (penicillin, 10,000 units/ml; streptomycin 10,000 mg/ml), all from
Thermo Fisher Scientific Inc. Cells were cultured under standard conditions (95% humidity,
5% CO2, 37˚C) and propagated by trypsinization with 1 mM EDTA/0.25% trypsin (w/v).
Photodynamic treatment and MTT assay. Cells were grown in 24-well plates and incu-
bated for 5 h with 0.3 mM MAL (Sigma-Aldrich, St. Louis, MO) in serum-free DMEM. Next,
cells were irradiated at intensities of 0.45 J/cm2 to 2.25 J/cm2 using a monochromatic light
source (635 nm ± 17 nm) with a multi-LED system. Control samples were subjected to identi-
cal conditions in the absence of irradiation and/or MAL.
MTT assay. Cell viability 24 h after photodynamic treatment was determined using the
MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazoliumbromide) assay. MTT solution
(50 μg/ml) was added to cell cultures, which were then and incubated at 37˚C for 3 h. After incu-
bation, the formazan precipitate was dissolved with dimethylsulfoxide (DMSO, Panreac) and
optical density was measured using a SpectraFluor (Tecan) plate reader (542 nm). Cellular toxicity
was expressed as the number of surviving cells relative to the number of non-treated control cells.
Indirect immunofluorescence (IF). For immunodetection of p53, β-catenin, and cyclin
D1, cells were fixed in 3.7% formaldehyde (4˚C) for 30 min, permeated with 0.1% Triton X-
100 in PBS (v/v) for 30 min, and incubated with primary (1:100; Cell Signaling Technology,
Inc. Danvers, MA) and secondary (1:250; Life Technologies, Eugene, Or, USA) antibodies. All
preparations were counterstained and mounted with ProLong-Gold with DAPI (Life Technol-
ogies, Eugene, Or, USA).
Western Blot (WB). Cellular extracts were obtained with RIPA buffer with Triton, pH 7.4
(Bioworld), containing phosphatase (PhosSTOP EASYpack, Roche) and protease (complete
ULTRA tablets Mini EDTA-free EASYpack, Roche) inhibitors, following the manufacturer’s
instructions. Protein concentration was determined using the BCA Protein Assay Kit (Pierce).
Cellular extracts were diluted in Laemmli buffer (Bio-Rad) and heated for 5 min at 98˚C. Elec-
trophoresis was performed using acrylamide/bisacrylamide gels in denaturing conditions
(SDS-PAGE) using a Mini-PROTEAN cell. Western blotting onto PVDF membranes (Bio-
Rad) was performed using a Transblot Turbo system (Bio-Rad). Membranes were incubated
with a after blocking solution consisting of skimmed milk in 0.1% TBS-Tween 20, with pri-
mary antibodies (anti-p53 and anti-β-catenin), and peroxidase-conjugated secondary antibod-
ies (Thermo Fisher), following the manufacturer’s instructions. Protein bands were visualized
by chemiluminiscence (ECL Pl us Kit, Amersham) using the high resolution ChemiDocTR
XRS+ system (Bio-Rad), and digitalized using Image Lab version 3.0.1 software (Bio-Rad).
Microscopy. Images were obtained using an epifluorescence microscope coupled to a
DP70 CCD camera (Olympus BX-61) equipped with corresponding filter sets: UV (360–370
nm excitation filter UG-1); blue (450–490 nm excitation filter BP 490); and green (570–590 nm
excitation filter 590 DM). Images were processed with Photoshop Extended CS5 12.0 (Adobe
Systems Inc., Mountain View, CA, USA). Quantitative image analysis was performed using
ImageJ 1.8 software (Wayne Rasband National Institutes of Health, Bethesda, MD, USA).
Statistical analysis
Data are expressed as the mean and standard deviation (SD) and dichotomous variables as
proportions. Associations between qualitative variables were assessed using the Chi-squared
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test or Fisher’s exact test. Given the small sample size, the Mann-Whitney U-test or Kruskal-
Wallis test for paired data were used to evaluate associations between quantitative variables.
Statistical significance was set at p<0.05. Variables for which a statistically significant associa-
tion with the response to PDT was observed were included in a multivariate analysis per-
formed using logistic regression. SPSS Statistics software (Version 19.0: IBM Corp, Armonk,
NY) was used for all analyses.
Ethical concerns
The present study was strictly observational and involved no change to the regular care regi-
men of participating patients. All data were fully anonymized before accesing them. The study
protocol was approved by the Arago´n Ethical Committee for Clinical Research (CEICA)
(CP-CI PI15/0219) and is part of a FIS research project (PI15/00974) S1 Fig.
Results
We retrospectively analyzed the response to MAL-PDT of 390 BCCs from 182 patients. The
overall response rate was 82.8%, with a mean follow-up time of 35.96 months (SD = 23.46;
range, 3 months to 6 years). In all cases the same light fluency (37 J/cm2) was used. The major-
ity of patients (87.4%) underwent 2 PDT sessions.
Clinical variables
The results are summarized in Table 1. The mean age of study participants was 72.82 years
(SD = 13), and was higher in non-responders (74.36 years) versus responders (69.22 years)
(p = 0.007). Sixty percent were male and 40% female. The mean (± SD) tumor size was
10.42 ± 7.75 mm. Lesion distribution was as follows: head and neck, 45.4%; extremities, 10.3%;
trunk, 16%. A correlation between lesion location and MAL-PDT response was observed: the
poorest response rate was seen for BCCs located on the nose (62.7%) and the best response
rate for those located on the trunk (94.7%) (p = 0.003). Phototype data were only available for
70 cases; the cure rate was higher for lighter versus darker phototypes (89.1% vs 66.7%;
p = 0.034).
Although the majority of patients (87.4%) underwent 2 PDT sessions, treatment response
in these patients differ significantly from that of patients who underwent more than 2 sessions
(p = 0.001).
Of the 390 BCCs included in the study, 278 were classified as nodular (nBCC) and 112 as
superficial (sBCC). Significantly higher response rates were observed for sBCCs (93.8%) versus
nBCCs (78.4%) (p<0.001).
Histological variables
Of the patients that received MAL-PDT, 49 responders and 14 non-responders had previously
undergone biopsy. The most common histological pattern was nBCC (74.6%). Higher
response rates were observed for sBCCs versus nBCCs (87.5% vs 74.5%; p = 0.487).
None of the histological variables were significantly associated with MAL-PDT response
(Table 1), except for peritumoral inflammatory infiltrate: a higher response rate (85.7%) was
observed for tumors with peritumoral inflammation (61.9%) (p = 0.032) (Fig 1A).
Immunohistochemical variables
p53 and β-catenin were the only immunohistological variables for which a statistically signifi-
cant association with the response to MAL-PDT was observed (Table 1). Positive p53
Resistances of basal cell carcinoma to PDT
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Table 1. Summary of the clinical, histological, and immunohistochemical variables analyzed in BCC patients, stratified by treatment-responsive and -nonrespon-
sive groups.
Clinical Variable Responder group Non-responder group P-value
Age years 69.22 (SD = 14.66) 74.36 (SD = 11.7) 0.007
Size� mm 10.29 (SD = 7.87) 10.89 (SD = 7.35) 0.445
Sex Male 195 (83.3%) 39 (16.7%) 0.742
Female 128 (82.1%) 28 (17.9%)
Phototype�� 1–3 49 (89.1%) 6 (10.9%) 0.034
4–6 10 (66.7%) 5 (33.3%)
Location Nose 37 (62.7%) 22 (37.3%) 0.003
Head and neck (except nose) 148 (83.6%) 29 (16.4%)
Trunk 108 (94.7%) 6 (5.3%)
Extremities 30 (75%) 10 (25%)
Tumor type Superficial BCC 105 (93.8%) 7 (6.3%) <0.001
Nodular BCC 218 (78.4%) 60 (21.6%)
Number of PDT sessions 1 33 (97.1%) 1 (2.9%) 0.001
2 282 (82.7%) 59 (17.3%)
�3 8 (53.3%) 7 (46.7%)
Histological variable Responder group Non-responder group P-value
Tumor thickness mm 1.44 (SD = 1.11) 1.86 (SD = 0.92) 0.081
Intratumoral necrosis Yes 9 (81.8%) 2 (18.2%) 1
No 40 (76.9%) 12 (23.1%)
Histological subtype Superficial BCC 14 (87.5%) 2 (12.5%) 0.487
Nodular BCC 35 (74.5%) 12 (25.5%)
Peritumoral stroma Loose 21 (80.8%) 5 (19.2%) 0.369
Dense 28 (77.8%) 8 (22.2%)
Mucinous 0 (0%) 1 (100%)
Loss of palisading Yes 2 (100%) 0 (0%) 1
No 47 (77%) 14 (23%)
Increased vascularization Yes 12 (85.7%) 2 (14.3%) 0.716
No 37 (75.5%) 12 (24.5%)
Elastosis Yes 16 (78.3%) 5 (21.7%) 0.861
No 26 (76.3%) 9 (23.7%)
Ulceration Yes 11 (68.8%) 5 (31.3%) 0.315
No 38 (80.9%) 9 (19.1%)
Inflammatory infiltrate Yes 36 (85.7%) 6 (14.3%) 0.032
No 13 (61.9%) 8 (38.1%)
Immunohistochemical variable Responder group Non-responder group P-value
CD31 Vessels in a high-power field (400×) 11 (SD = 8.48) 9,78(SD = 6.93) 0.626
P53 Positive 44 (84.6%) 8 (15.4%) 0.011
Negative 5 (45.5%) 6 (54.5%)
Mean (SD) 34.39 (SD = 34.34) 22.93 (SD = 29.34) 0.261
Ki-67 Positive 48 (77.4%) 14 (22.6%) 1
Negative 1 (100%) 0 (0%)
Mean (SD) 31.71 (SD = 22.41) 30.57 (SD = 26.69) 0.872
COX-2 Positive 20 (69%) 9 (31%) 0.12
Negative 29 (85.3%) 5 (14.7%)
EGFR Moderate to intense positive 30 (76.9%) 9 (23.1%) 0.835
Mild positive-Negative 19 (79.2%) 5 (20.8%)
(Continued)
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immunostaining was observed in 84.6% of responders, but only 15.4% of non-responders
(p = 0.011) (Fig 1B). β-catenin immunostaining was moderate or intense in 84.6% of respond-
ers and in 33.3% of non-responders (p = 0.096). In 3 cases (4.83%), none of which responded
to MAL-PDT (p = 0.01), a pattern of β-catenin staining with peripheral palisading reinforce-
ment was observed (Fig 1C).
Multivariate analysis revealed that the following variables were significantly associated with
response to PDT: age, nBCC, presence of peritumoral inflammatory infiltrate, and p53 immu-
nopositivity. Patients with positive p53 immunostaining were 68.54 times more likely to
achieve cure than p53-negative patients (CI95% 2.94–159.8) (Table 2).
In vitro studies
As described above, negative p53 immunostaining and a specific pattern of β-catenin expres-
sion were associated with a poorer response to MAL-PDT in BCC patients. Next, we sought to
corroborate this finding in 2 murine BCC cell lines: ASZ (p53-positive) and BSZ (p53-nega-
tive).7 First, using IF and WB (p<0.001 in both cases), we confirmed that p53 was expressed
only in ASZ cells (Fig 2A and Fig 2B).
β-catenin expression was observed in both cell lines, primarily in the cell membrane,
although diffuse cytoplasmic expression was also detected. The β-catenin signal was more
intense in BSZ cells, in which higher levels of expression were confirmed by WB (p<0.05)
(Fig 2B).
Levels of p53 and β-catenin expression were correlated with those of cyclin D1 (Fig 2A). In
the p53-negative BSZ cell line, in which β-catenin expression was greatest, the mean fluores-
cence intensity of cyclin D1 was significantly higher than that observed in ASZ cells (p
<0.001) (Fig 2C).
Cell viability after photodynamic treatment
ASZ and BSZ cells were incubated with 0.3 mM MAL for 5 h and subsequently irradiated with
different doses of red light. MTT assay revealed no effect on the viability of ASZ or BSZ cells of
successive exposure to the 2 components of MAL-PDT (Fig 3A). PDT (MAL 0.3 mM; 2.25 J/
cm2) resulted in decreases in cell viability to 35% (ASZ cells) and 66% (BSZ) of corresponding
control levels (p<0.01). The difference in response was also seen in their cell morphology,
after PDT; ASZ showed a major decrease of live cells and an increase of cellular damage than
BSZ (Fig 3B).
Table 1. (Continued)
β-catenin (Intensity) Moderate to intense positive 33 (84.6%) 6 (15.4%) 0.096
Mild positive-Negative 16 (66.7%) 8 (33.3%)
β-catenin (Distribution) Peripheral reinforcement of the islets 0 (0%) 3 (100%) 0.01
Non peripheral reinforcement of the islets 48 (81.6%) 11 (18.6%)
Survivin (Intensity) Moderate to intense positive 30 (76.9%) 9 (23.1%) 0.903
Mild positive-Negative 18 (78.3%) 5 (21.7%)
Survivin (Distribution) Focal 10 (83.3%) 2 (16.7%) 0.715
Diffuse 37 (75.5%) 12 (24.5%)
�Size and
��phototype data were only available for 214 and 70 BCCs, respectively.
https://doi.org/10.1371/journal.pone.0215537.t001
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Discussion
In this study we retrospectively evaluated the effects of MAL-PDT on different clinical-patho-
logical and molecular characteristics of BCC. Analysis of clinical variables revealed that the
response of nBCCs was poorer than that of sBCCs. Other factors associated with a poorer
response were location of the tumor in area H, older age, darker phototype, and a greater num-
ber of MAL-PDT sessions. The only histological variable associated with a poor response was
the absence of peritumoral lymphocytic inflammatory infiltrate. Finally, we found that nega-
tive p53 immunoreactivity and a β-catenin pattern with peripheral reinforcement of islands of
basaloid cells were associated with tumor resistance to PDT. These molecular findings were
corroborated in vitro by IF and WB in BCC cell lines.
The rate of response to PDT was influenced by the histological subtype of BCC (87.5% for
sBCC vs. 74.5% for nBCC). Previous studies have reported higher cure rates for sBCCs (82–
100%) [9–11] than nBCCs (33–100%) [11–18] after PDT. This observation may be directly
related to other parameters, such as tumor thickness. Morton et al. proposed that lesion thick-
ness influences the response to topical PDT, setting a thickness limit of 2 mm.[19]
The effectiveness of PDT may be limited by other clinical and epidemiologic factors, includ-
ing age and tumor location. According to our findings, the H area is the least suitable area for
PDT, it can be explained because they are embryological fusion areas with a tendency to invade
in depth or maybe the locations of lesions reflect accumulation of UV lesions and hence, status
of mutations.[20] In our series of 472 tumors (BCC and Bowen disease) treated with
MAL-PDT, we found that more advanced age was a predictor of a poor response. Supporting
this view, Niessen et al. found that PDT was more effective in younger patients, and reported
an age-associated decrease in the formation of PpIX after application of MAL or BF-200.[21]
However, other authors have reported no such association between older age and a poorer
treatment response or higher recurrence rate.[22]
Our results suggest that darker phototypes may be associated with a poorer response to
MAL-PDT. This may be the result of competitive absorption of light by melanin in the basal
layer of the epidermis, and a consequent decrease in the total amount of energy that reaches
deeper dermal lesions.[23] It should be borne in mind that melanin is an endogenous antioxi-
dant of the skin, and may scavenge reactive oxygen species produced during PDT, thus limit-
ing treatment efficacy.[24]
We found that clinical outcome was not improved in patients who received more than 2
PDT sessions. Therefore instead of insisting it has been shown that the combination of PDT
with other therapies increases the likelihood of success, diminishing resistance.[2]
Fig 1. (a) Peritumoral inflammation surrounding basal cell carcinoma in a MAL-PDT-sensitive BCC (10×). (b) p53 immunostaining in a
MAL-PDT responsive BCC: 97% of cells exhibit positive p53 immunostaining (5×). (c) Intense β-catenin immunostaining in a MAL-PDT-
sensitive BCC (10×) and (d) enhanced peripheral palisading in a MAL-PDT-resistant BCC (40x). Bar charts depict levels of perilesional
inflammatory infiltrate, p53 immunoexpression, and the intensity and distribution of β-catenin immunostaining in BCCs treated with
MAL-PDT (responsive and nonresponsive). Scale bar: 200 μm (A and C), 500 μm (B) and 100 μm (D).
https://doi.org/10.1371/journal.pone.0215537.g001
Table 2. Results of the multiple logistic regression model showing variables significantly associated with treatment response: age, BCC subtype, presence of inflam-
matory infiltrate, and positive p53 immunostaining.
Coefficients Estimation Standard error p-value Odds Ratio (CI95%)
Age <63 years 0.263 0.096 0.006 1.3 (1.07–1.57)
Nodular BCC -6.28 2.89 0.029 0.02 (0.0–0.53)
Inflammatory infiltrate 3.59 1.52 0.018 36.4 (1.84–716.5)
P53-positive 4.23 1.61 0.009 68.54 (2.94–159.8)
https://doi.org/10.1371/journal.pone.0215537.t002
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We observed a significant correlation between the presence of intense inflammatory lym-
phocytic infiltrate and a better response to treatment, supporting previous findings by our
group in squamous cell carcinomas (SCCs) treated with MAL-PDT.[4] In other tumor types,
such as melanoma,[25] the presence of inflammatory infiltrate is a proposed prognostic factor,
and may constitute an antitumor response from the host, contributing to or even enhancing
the effect of PDT.[26]
Positive p53 immunoexpression was detected in 15.4% of MAL-PDT-resistant BCCs versus
84.6% of MAL-PDT-responsive BCCs, a difference that proved statistically significant. This
finding was corroborated in the in vitro study, in which a better response to PDT was observed
in the p53-positive (ASZ) than the p53-negative (BSZ) BCC cell line. We previously reported
similar findings in Bowen’s disease patients treated with MAL-PDT and in the SCC cell lines
SCC-13 and A-431.[27] Furthermore, the findings of multiple in vivo studies suggest that p53
may play a role in the observed increase in PpIX levels and subsequent cell death with
increased selective accumulation.[28–31]
β-catenin expression has been linked to tumor aggressiveness [32]: intranuclear β-catenin
expression is correlated with increased tumor proliferation and aggressiveness, and is observed
in the most aggressive subtypes. In BCCs that did not respond to MAL-PDT we identified a
Fig 2. Expression of p53, β-catenin and ciclin D1 in BCC mice lines. (A) Expression pattern of p53, β-catenin and ciclin D1 on ASZ and BSZ cells by
immunofluorescence. Scale bar: 20um. (B) Protein quantification by Western Blot of (a) p53 and (b) β-catenin. Load control: β-actin. (C) Relative fluorescence of cyclin
d1 expression by immunofluorescence. �p< 0.05; ���p< 0.001.
https://doi.org/10.1371/journal.pone.0215537.g002
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characteristic β-catenin immunostaining pattern at the advancing border with increased pali-
sading. Ciurea et al.[32], El-Bahrawy et al.[33] and Oh et al.[34] reported that in BCCs with an
infiltrative component β-catenin immunostaining is increased at the advancing border and at
the periphery of nodules in more indolent variants, strongly supporting a role of β-catenin in
BCC invasion. At cellular level, higher expression of total β-catenin was associated with the
absence of p53 expression in BSZ cells, confirming the evidences in bibliography that link the
absence of p53 with a higher expression of Wnt/β-catenin factors.[35–36]
Compared with ASZ cells, cyclin D1 expression was higher in BSZ cells (in which p53 is
absent and β-catenin expression is increased). Higher levels of cyclin D1 expression have been
associated with a poorer prognosis in breast, ovarian, and esophageal carcinomas.[36–38]
Limitations of the present study include the significant number of cases that were lost to fol-
low-up before 6 years, precluding analysis of factors influencing the long-term response to
MAL-PDT.
In conclusion, our study identifies several possible biomarkers or histological features
indicative of a poor BCC response to MAL-PDT that could be used to select patients who will
most benefit from this treatment modality. These include advanced age (>63 years), nBCC,
absent p53 expression, β-catenin peripheral palisading of basal cell islands reinforcement, and
the absence of peritumoral infiltrate.
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